Hikma Pharmaceuticals PLC
LSE:HIK
Hikma Pharmaceuticals PLC
LSE:HIK
Price:
1 994 GBX
0.66%
Market Closed
Updated:
May 11, 2024
Hikma Pharmaceuticals PLC
Cash from Investing Activities
|
Hikma Pharmaceuticals PLC
Cash from Investing Activities Peer Comparison
Comparables:
GSK
AZN
VRNA
INDV
DPH
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Investing Activities
-$333m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-11%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Investing Activities
-£1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Investing Activities
-$5.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Cash from Investing Activities
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Cash from Investing Activities
$54m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cash from Investing Activities
-£426.2m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-36%
|
See Also
What is Hikma Pharmaceuticals PLC's Cash from Investing Activities?
Cash from Investing Activities
-333m
USD
-333m
USD
Based on the financial report for Dec 31, 2023, Hikma Pharmaceuticals PLC's Cash from Investing Activities amounts to -333m USD.
What is Hikma Pharmaceuticals PLC's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-11%
-11%
Over the last year, the Cash from Investing Activities growth was 45%. The average annual Cash from Investing Activities growth rates for Hikma Pharmaceuticals PLC have been -6% over the past three years , -28% over the past five years , and -11% over the past ten years .
You don't have any saved screeners yet
